About the Company
We do not have any company description for Estrella Immunopharma, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Estrella Immunopharma, Inc.
ESLA Estrella Immunopharma, Inc. - Seeking Alpha
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate ...
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a ...
Estrella Immunopharma, Inc., a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® T-cell therapies to treat cancer and autoimmune diseases, today announced that ...
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW ... - Morningstar
About Estrella Immunopharma, Inc. Estrella is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® T-cell therapies to treat cancers and autoimmune diseases.
Estrella Immunopharma Achieves Complete Response in First Patient ...
Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-t ...
Estrella Immunopharma Announces Activation of Additional Site ... - Nasdaq
Estrella Immunopharma, Inc., a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® T-cell therapies to treat cancer and autoimmune diseases, today announced the ...
ESLA - Estrella Immunopharma Inc News | Morningstar
News Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma Business Wire Jun 5, 2025, 12:00:00 PM ...
Estrella Immunopharma Inc. (ESLA) Stock Price Today - WSJ
View the latest Estrella Immunopharma Inc. (ESLA) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Estrella Immunopharma Inc. Wt Financials | ESLAW | Barron's
Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies for patients with cancers and autoimmune diseases.
Estrella Immunopharma (NASDAQ:ESLAW) Stock, Short Interest Report
Short interest in Estrella Immunopharma Inc (NASDAQ:ESLAW) decreased during the last reporting period, falling from 4.35K to 4.23K. This put -% of the company's publicly available shares short.
Similar Companies
Loading the latest forecasts...